JP2013506675A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506675A5
JP2013506675A5 JP2012532248A JP2012532248A JP2013506675A5 JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5 JP 2012532248 A JP2012532248 A JP 2012532248A JP 2012532248 A JP2012532248 A JP 2012532248A JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5
Authority
JP
Japan
Prior art keywords
antibody
notch3
notch1
antagonist
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012532248A
Other languages
English (en)
Japanese (ja)
Other versions
JP6025563B2 (ja
JP2013506675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/050610 external-priority patent/WO2011041336A2/en
Publication of JP2013506675A publication Critical patent/JP2013506675A/ja
Publication of JP2013506675A5 publication Critical patent/JP2013506675A5/ja
Application granted granted Critical
Publication of JP6025563B2 publication Critical patent/JP6025563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012532248A 2009-09-30 2010-09-29 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性癌の治療 Active JP6025563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30
US61/247,298 2009-09-30
PCT/US2010/050610 WO2011041336A2 (en) 2009-09-30 2010-09-29 Methods of treating cancer using notch antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015011573A Division JP2015145362A (ja) 2009-09-30 2015-01-23 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療
JP2016138236A Division JP2017014219A (ja) 2009-09-30 2016-07-13 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療

Publications (3)

Publication Number Publication Date
JP2013506675A JP2013506675A (ja) 2013-02-28
JP2013506675A5 true JP2013506675A5 (https=) 2013-10-17
JP6025563B2 JP6025563B2 (ja) 2016-11-16

Family

ID=43127684

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012532248A Active JP6025563B2 (ja) 2009-09-30 2010-09-29 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性癌の治療
JP2015011573A Withdrawn JP2015145362A (ja) 2009-09-30 2015-01-23 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療
JP2016138236A Pending JP2017014219A (ja) 2009-09-30 2016-07-13 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015011573A Withdrawn JP2015145362A (ja) 2009-09-30 2015-01-23 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療
JP2016138236A Pending JP2017014219A (ja) 2009-09-30 2016-07-13 Notch3アンタゴニストを用いたNotch1アンタゴニスト耐性がんの治療

Country Status (21)

Country Link
US (1) US9200071B2 (https=)
EP (1) EP2483311B1 (https=)
JP (3) JP6025563B2 (https=)
KR (1) KR101782180B1 (https=)
CN (1) CN102630229B (https=)
AU (1) AU2010300747A1 (https=)
BR (1) BR112012007252A2 (https=)
CA (1) CA2775880A1 (https=)
CL (1) CL2012000800A1 (https=)
CO (1) CO6531430A2 (https=)
CR (1) CR20120213A (https=)
EC (1) ECSP12011858A (https=)
ES (1) ES2580229T3 (https=)
IL (1) IL218662A0 (https=)
MA (1) MA33973B1 (https=)
MX (1) MX342250B (https=)
PE (1) PE20120998A1 (https=)
PH (1) PH12012500574A1 (https=)
RU (1) RU2012117619A (https=)
WO (1) WO2011041336A2 (https=)
ZA (1) ZA201201984B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133796C1 (ru) * 1997-10-09 1999-07-27 ОАО "Томский электромеханический завод им.В.В.Вахрушева" Люк смотрового колодца
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
EP3431501A1 (en) 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies
AU2011342799B2 (en) 2010-12-15 2016-06-09 Wyeth Llc Anti-Notch1 antibodies
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
EP3611189A1 (en) * 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
WO2014151606A2 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EA201691610A8 (ru) 2014-02-12 2018-05-31 Дженентек, Инк. Анти-jagged1 антитела и способы применения
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
US11142573B2 (en) * 2016-04-29 2021-10-12 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibody
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
PE20080891A1 (es) * 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム NotchまたはNumb特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102112490B (zh) * 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
EP3431501A1 (en) * 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies

Similar Documents

Publication Publication Date Title
JP2013506675A5 (https=)
RU2012117619A (ru) ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2015533788A5 (https=)
JP2014512809A5 (https=)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ712765A (en) Antibodies that bind csf1r
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
RU2014147867A (ru) Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2017535257A5 (https=)
JP2014205674A5 (https=)
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2013542194A5 (https=)
NZ611269A (en) Neutralizing anti-ccl20 antibodies
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2013538057A5 (https=)
JP2014526898A5 (https=)
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
JP2015511962A5 (https=)
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1